Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.

Abstract

Daptomycin demonstrated in vitro (MIC(90), 4 μg/ml) and in vivo activities against Bacillus anthracis. Twice-daily treatment with a dose of 50 mg/kg of body weight was begun 24 h after challenge and continued for 14 or 21 days; results were compared to those for controls treated with phosphate-buffered saline or ciprofloxacin. Day 43 survival rates were 6/10 mice for the 14-day and 9/10 mice for the 21-day treatment groups, compared to survival with ciprofloxacin: 8/10 and 9/10 mice, respectively. Culture results from tissues removed at the termination of the experiment were negative.

• Authors: Henry S Heine, Jennifer Bassett, Lynda Miller, Bret K Purcell, W Russell Byrne
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 54 Issue 10 Pg. 4471-3 (Oct 2010) ISSN: 1098-6596 [Electronic] United States
• PMID: 20643899 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Anti-Bacterial Agents
• Ciprofloxacin
• Daptomycin

Topics

• Animals
• Anthrax (drug therapy)
• Anti-Bacterial Agents (therapeutic use)
• Bacillus anthracis (drug effects, pathogenicity)
• Ciprofloxacin (therapeutic use)
• Daptomycin (therapeutic use)
• Female
• Mice
• Mice, Inbred BALB C
• Spores, Bacterial (drug effects, pathogenicity)